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Abstract
BACKGROUND—Brentuximab vedotin is an anti-CD30 antibody–drug conjugate that has been 
approved for relapsed and refractory Hodgkin’s lymphoma.
METHODS—We conducted an open-label, multicenter, randomized phase 3 trial involving 
patients with previously untreated stage III or IV classic Hodgkin’s lymphoma, in which 664 were 
assigned to receive brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) and 
670 were assigned to receive doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). The 
primary end point was modified progression-free survival (the time to progression, death, or 
noncomplete response and use of subsequent anticancer therapy) as adjudicated by an independent 
review committee. The key secondary end point was overall survival.
RESULTS—At a median follow-up of 24.9 months, 2-year modified progression-free survival 
rates in the A+AVD and ABVD groups were 82.1% (95% confidence interval [CI], 78.7 to 85.0) 
and 77.2% (95% CI, 73.7 to 80.4), respectively, a difference of 4.9 percentage points (hazard ratio 
for an event of progression, death, or modified progression, 0.77; 95% CI, 0.60 to 0.98; P = 0.03). 
There were 28 deaths with A+AVD and 39 with ABVD (hazard ratio for interim overall survival, 
0.72 [95% CI, 0.44 to 1.17]; P = 0.19). All secondary efficacy end points trended in favor of A
+AVD. Neutropenia occurred in 58% of the patients receiving A+AVD and in 45% of those 
receiving ABVD; in the A+AVD group, the rate of febrile neutropenia was lower among the 83 
patients who received primary prophylaxis with granulocyte colony-stimulating factor than among 
those who did not (11% vs. 21%). Peripheral neuropathy occurred in 67% of patients in the A
+AVD group and in 43% of patients in the ABVD group; 67% of patients in the A+AVD group 
who had peripheral neuropathy had resolution or improvement at the last follow-up visit. 
Pulmonary toxicity of grade 3 or higher was reported in less than 1% of patients receiving A+AVD 
and in 3% of those receiving ABVD. Among the deaths that occurred during treatment, 7 of 9 in 
the A+AVD group were associated with neutropenia and 11 of 13 in the ABVD group were 
associated with pulmonary-related toxicity.
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CONCLUSIONS—A+AVD had superior efficacy to ABVD in the treatment of patients with 
advanced-stage Hodgkin’s lymphoma, with a 4.9 percentage-point lower combined risk of 
progression, death, or noncomplete response and use of subsequent anticancer therapy at 2 years. 
(Funded by Millennium Pharmaceuticals and Seattle Genetics; ECHELON-1 ClinicalTrials.gov 
number, NCT01712490; EudraCT number, 2011-005450-60.)
Outcomes for patients with advanced-stage Hodgkin’s lymphoma have improved 
dramatically over the past half century.1 Although regional differences exist, the most 
commonly used frontline regimen — doxorubicin, bleomycin, vinblastine, and dacarbazine 
(ABVD) — has not been modified since its original description in 1975.
Up to 30% of patients with stage III or IV Hodgkin’s lymphoma harbor refractory disease or 
relapse after frontline treatment with ABVD.2–4 Bleomycin is associated with unpredictable 
and sometimes fatal pulmonary toxicity and is often dropped from later cycles of 
chemotherapy owing to pulmonary symptoms.5,6 Recent studies suggest that response-
adapted therapy guided by interim positron-emission tomography (PET) with 18F-
fluorodeoxyglucose can provide a more individualized treatment approach, in which 
treatment intensity is de-escalated or intensified depending on the early response to 
treatment.7,8 Efforts are also being made to incorporate new drugs into established backbone 
regimens to improve efficacy and reduce toxicity.9
CD30 is a characteristic surface antigen expressed on Reed–Sternberg cells in classic 
Hodgkin’s lymphoma.10 Brentuximab vedotin is an antibody–drug conjugate composed of 
an anti-CD30 monoclonal antibody conjugated by a protease-cleavable linker to the 
microtubule-disrupting agent monomethyl auristatin E. Brentuximab vedotin has been 
approved for the treatment of classic Hodgkin’s lymphoma after failure of autologous stem-
cell transplantation or after two or more multiagent chemotherapy regimens in patients who 
are not candidates for transplantation. The drug has also been approved as post-
transplantation consolidation therapy for patients with Hodgkin’s lymphoma who are at 
increased risk for relapse or progression.11,12
A previous phase 1, dose-escalation trial involving patients with advanced Hodgkin’s 
lymphoma evaluated the use of frontline brentuximab vedotin combined with either ABVD 
or doxorubicin, vinblastine, and dacarbazine (AVD).13 Brentuximab vedotin plus AVD (A
+AVD) had an acceptable side-effect profile and resulted in complete response in 24 of 25 
patients (96%). Long-term follow-up showed a 5-year failure-free survival rate of 92% and 
an overall survival rate of 100% with A+AVD.14 On the basis of these findings, 
ECHELON-1, a large, international, open-label, randomized, multicenter, phase 3 trial was 
conducted to compare A+AVD with ABVD as frontline therapy in patients with stage III or 
IV classic Hodgkin’s lymphoma.
METHODS
TRIAL DESIGN
Patients were randomly assigned in a 1:1 ratio to receive A+AVD (1.2 mg of brentuximab 
vedotin per kilogram of body weight, 25 mg of doxorubicin per square meter of body-
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surface area, 6 mg of vinblastine per square meter, and 375 mg of dacarbazine per square 
meter) or ABVD (25 mg of doxorubicin per square meter, 10 units of bleomycin per square 
meter, 6 mg of vinblastine per square meter, and 375 mg of dacarbazine per square meter) 
intravenously on days 1 and 15 of each 28-day cycle for up to 6 cycles. Brentuximab vedotin 
was administered over 30 minutes, starting within approximately 1 hour after completion of 
AVD. Dose reductions and modifications are described in Table S1 in the Supplementary 
Appendix, available with the full text of this article at NEJM.org. Patients were stratified 
according to region (Americas vs. Europe vs. Asia) and International Prognostic Score (IPS) 
risk group (low risk vs. intermediate risk vs. high risk). The IPS ranges from 0 to 7, with a 
score of 0 or 1 indicating low risk of treatment failure, a score of 2 or 3 intermediate risk, 
and a score of 4 to 7 high risk (see Table S2 in the Supplementary Appendix).15 The results 
of PET conducted at the end of the second 28-day cycle of treatment (hereafter referred to as 
PET2) guided an optional switch to alternative frontline therapy at the treating physician’s 
discretion for patients with a Deauville score of 5. The Deauville score is a 5-point scale on 
which higher scores indicate greater uptake of 18F-fluorodeoxyglucose at involved sites on 
PET. A score of 1 indicates no uptake, a score of 2 uptake at an initial site that is less than or 
equal to the uptake at the mediastinum, a score of 3 uptake at an initial site that is greater 
than uptake at the mediastinum but less than or equal to uptake at the liver, a score of 4 
uptake at an initial site that is moderately increased as compared with the uptake at the liver, 
and a score of 5 markedly increased uptake at any site or uptake at a new site of disease.16
OVERSIGHT
The ECHELON-1 trial was conducted in accordance with regulatory requirements; the 
protocol (available at NEJM.org) was approved by institutional review boards and ethics 
committees at individual sites, and adhered to Good Clinical Practice guidelines (as defined 
by the International Conference on Harmonisation). A steering committee and an 
independent data and safety monitoring committee oversaw the conduct of the trial, and all 
the patients provided written informed consent.
The trial was designed by a committee consisting of six authors plus representatives of the 
sponsors, Millennium Pharmaceuticals and Seattle Genetics. Data were collected and trial 
procedures were overseen by trial investigators. Data were verified by the sponsors, analyzed 
by sponsor statisticians, and interpreted by academic authors and sponsor representatives. 
The manuscript was prepared by the authors with the assistance of a medical writer funded 
by the sponsors. All the authors had full access to the data, vouch for the completeness and 
accuracy of the data and adherence of the trial to the protocol, and had final responsibility 
for the manuscript content and the decision to submit the manuscript for publication.
PATIENTS
Patients were 18 years of age or older and had histologically confirmed advanced classic 
Hodgkin’s lymphoma (Ann Arbor stage III or IV, as determined on a 4-point scale, with 
higher stages indicating more widespread disease),17 according to the World Health 
Organization classification system.18 Patients who had not been previously treated with 
systemic chemotherapy or radiotherapy were eligible. Patients were required to have an 
Eastern Cooperative Oncology Group performance status of 0, 1, or 2 (on a scale of 0 to 5, 
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with higher scores indicating greater disability)19; satisfactory absolute neutrophil counts 
(≥1500 per cubic millimeter), platelet counts (≥75,000 per cubic millimeter), and 
hemoglobin levels (≥8 g per deciliter) (with the exception of patients with involvement of 
the marrow); satisfactory levels of markers of liver function (total bilirubin level, <1.5 times 
the upper limit of normal [with the exception of patients with Gilbert’s syndrome] and 
alanine aminotransferase or aspartate aminotransferase levels, <3 times the upper limit of 
normal [with the exception of patients with involvement of the liver]); and satisfactory levels 
of markers of kidney function (serum creatinine level, <2.0 mg per deciliter [177 μmol per 
liter]; creatinine clearance or calculated creatinine clearance, >40 ml per minute; or both). 
Patients with nodular lymphocyte-predominant Hodgkin’s lymphoma were ineligible, as 
were those with peripheral sensory or motor neuropathy, a positive pregnancy test, known 
cerebral or meningeal disease, any evidence of residual disease from another cancer, 
diagnosis of another cancer within 3 years before the first dose, or any clinically relevant 
cardiovascular conditions.
END POINTS
The primary end point was modified progression-free survival, defined as time to disease 
progression, death, or modified progression (with the latter defined as evidence of 
noncomplete response after completion of frontline therapy according to review by an 
independent committee, followed by subsequent anticancer therapy). This end point was 
chosen specifically to evaluate the effectiveness of the primary chemotherapy and 
encompasses three possible outcomes, each of which represents a failure of the primary 
chemotherapy to eliminate Hodgkin’s lymphoma: documented progression20 at any time 
after initiation of primary chemotherapy, death from any cause, and detection of a response 
that was less than complete at the end of primary chemotherapy (Deauville score of 3, 4, or 
5 on a PET scan), followed by the delivery of subsequent anticancer therapy. The latter 
outcome was considered to be an event only if noncomplete response was confirmed during 
review by an independent committee, whose members were unaware of group assignments, 
and was followed by the delivery of subsequent anticancer treatment that was not specified 
in the protocol. Additional justifications for, and explanation of, this choice of primary end 
point are provided in the Supplementary Appendix. Timing of the modified progression 
event was the date on which the first PET scan was obtained after completion of frontline 
therapy, showing the absence of complete response. In the absence of disease progression, a 
switch to an alternative frontline therapy before completion of primary chemotherapy with 
the randomized regimen was not considered to be an event.
The key secondary end point was overall survival, defined as the time from randomization to 
death from any cause. Other secondary and exploratory end points are described in the 
protocol.
ASSESSMENTS
Response and progression were evaluated in accordance with the Revised Response Criteria 
for Malignant Lymphoma.20 Computed tomographic scans were obtained at screening, at the 
end of cycle 2, after administration of the last dose of frontline therapy, and during the 
follow-up period (every 3 months for the first year and every 6 months thereafter). PET 
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scans were obtained at screening, at the end of cycle 2, and at the end of treatment. Safety 
outcomes were the incidence of adverse events (defined according to the Medical Dictionary 
for Regulatory Activities [MedDRA], version 19.0, and the National Cancer Institute 
Common Terminology Criteria for Adverse Events, version 4.03) and changes in vital signs 
and laboratory test results.
STATISTICAL ANALYSIS
According to statistical calculations, an estimated 260 modified progression-free survival 
events would give the trial 90% power to detect a hazard ratio for disease progression, death, 
or modified progression of 0.67 at a one-sided significance level of 0.025. The trial was 
powered on the following assumption: a 2-year modified progression-free survival of 81% 
for patients in the A+AVD group and 73% for patients in the ABVD group. Randomization 
of approximately 1240 patients was planned to achieve (with 95% probability) 260 modified 
progression-free survival events. The primary end point was summarized with the use of the 
Kaplan–Meier method and evaluated with the use of a stratified log-rank test. A stratified 
Cox regression model was used to estimate the hazard ratio and the 95% confidence interval 
for the treatment effect. The stratification factors included region and IPS risk group at 
baseline. The interim analysis for overall survival was to be performed if the result of the 
primary analysis was statistically significant. The final overall survival analysis will be 
performed after 112 deaths have occurred. Overall type I error for the overall survival 
analysis will be controlled with the use of the O’Brien–Fleming method with the Lan–
DeMets alpha spending function.
All efficacy evaluations were performed in the intention-to-treat population unless otherwise 
specified. Safety was analyzed in patients who received at least one dose of the trial drug 
(the safety population).
RESULTS
PATIENTS
From November 19, 2012, through January 13, 2016, a total of 1334 patients at 218 sites in 
21 countries were randomly assigned to receive A+AVD (664 patients) or ABVD (670 
patients) (intention-to-treat population) (Fig. S1 in the Supplementary Appendix). Overall, 
58% of the patients were men, 64% had stage IV disease, 62% had extranodal involvement 
at diagnosis, 58% had B symptoms (i.e., weight loss, night sweats, and fever), and the 
median age was 36 years (34% of patients were ≥45 years of age). Baseline characteristics 
were generally well balanced between the two groups (Table 1, and Table S3 in the 
Supplementary Appendix).
EFFICACY
After a median follow-up of 24.9 months (range, 0 to 49.3), the rate of the primary end point 
of independently determined modified progression-free survival was significantly higher in 
the A+AVD group than in the ABVD group (2-year modified progression-free survival rate, 
82.1% [95% confidence interval {CI}, 78.7 to 85.0] vs. 77.2% [95% CI, 73.7 to 80.4]; 
hazard ratio for progression, death, or modified progression, 0.77 [95% CI, 0.60 to 0.98]; P 
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= 0.03), corresponding to a 23% risk reduction (Fig. 1A). Events of progression, death, or 
modified progression occurred in 117 patients in the A+AVD group and in 146 patients in 
the ABVD group; disease progression occurred in 90 and 102 patients, respectively; death 
from any cause in 18 and 22 patients, respectively, and receipt of subsequent anticancer 
therapy after failure to achieve a complete response at the completion of frontline therapy 
(modified progression) in 9 and 22 patients, respectively (Table 2). The majority (71%) of 
these subsequent anticancer therapies consisted of salvage chemotherapy (7 of 9 patients in 
the A+AVD group and 15 of 22 patients in the ABVD group), with radiotherapy given to the 
remainder of patients in both groups (Table S4 in the Supplementary Appendix). Modified 
progression events assigned because of an end-of-treatment PET scan and subsequent 
treatment were predominantly associated with a Deauville score of 4 or 5 (a score of 3 was 
recorded in 7 of 31 patients [23%], a score of 4 in 10 of 31 patients [32%], and a score of 5 
in 14 of 31 patients [45%]); these events also met the criteria for a progression event 
according to investigator assessment. Of note, only 7 of the 21 patients with a Deauville 
score of 3 on the end-of-treatment PET scan went on to receive additional therapy and were 
therefore determined to have had a modified progression event (2 patients in the A+AVD 
group and 5 patients in the ABVD group; Tables 2 and 3).
According to investigator assessment, the 2-year modified progression-free survival rate was 
81.0% (95% CI, 77.6 to 83.9) with the A+AVD regimen versus 74.4% (95% CI, 70.7 to 
77.7) with the ABVD regimen, corresponding to a 27% lower overall risk of an event among 
patients treated with A+AVD than among those treated with ABVD (hazard ratio for 
progression, death, or modified progression, 0.73; 95% CI, 0.57 to 0.92; P = 0.007) (Fig. 
1B). There was 91% concordance between independent review and investigator 
determination of a modified progression-free survival event.
Prespecified subgroup analyses of modified progression-free survival showed a hazard ratio 
of less than 1 for the A+AVD regimen versus the ABVD regimen in the majority of 
subgroups (Fig. 2). Certain subgroups of patients appeared to benefit more with A+AVD 
than with ABVD. These subgroups included patients from North America, patients with 
involvement of more than one extranodal site, patients with an IPS indicating a high risk of 
treatment failure (scores of 4 to 7), men, patients with stage IV disease, and patients younger 
than 60 years of age. The rates of negativity at PET2 (Deauville score, 1 to 3) were 89% 
with A+AVD versus 86% with ABVD.
There were 28 deaths in the A+AVD group (9 during treatment [within 30 days after the last 
dose of frontline therapy] and 19 during follow-up [31 days or more after the last dose of 
frontline therapy]) and 39 deaths in the ABVD group (13 during treatment and 26 during 
follow-up). The interim 2-year overall survival rate for the A+AVD group was 96.6% (95% 
CI, 94.8 to 97.7) and that for the ABVD group was 94.9% (95% CI, 92.9 to 96.4), which 
corresponded to a reduction in the risk of death of 28% in favor of the A+AVD regimen 
(hazard ratio, 0.72; 95% CI, 0.44 to 1.17; P = 0.19) (Fig. S2 in the Supplementary 
Appendix). Results for other secondary end points are shown in Table 3. Only 15 of 662 
patients who received A+AVD and 9 of 659 patients who received ABVD switched to 
alternative chemotherapy during frontline therapy for reasons other than progressive disease 
(a Deauville score of 5 in 1 of 15 and 4 of 9 patients, respectively; adverse events in 12 of 15 
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and 1 of 9 patients, respectively; and other reasons in 2 of 15 and 4 of 9 patients, 
respectively) (Table S5 in the Supplementary Appendix).
Overall, fewer patients in the A+AVD group than in the ABVD group received subsequent 
anticancer therapies. Recipients of these therapies in the A+AVD group versus the ABVD 
group were as follows: radiation (in 52 patients in each group), chemotherapy (66 vs. 99), 
high-dose chemotherapy plus transplantation (36 vs. 54), immunotherapy (10 vs. 16), and 
chemotherapy plus radiation (2 vs. 3).
SAFETY
The median duration of treatment and the number of completed cycles were similar in the 
two groups (Table S6 in the Supplementary Appendix). The proportions of patients who 
received the regimens as intended, without dose modification such as delays, holds, or 
reductions, are shown in Table S6 in the Supplementary Appendix.
The safety profiles for both groups are summarized in Table 4, and in Table S7 in the 
Supplementary Appendix. Overall, neutropenia was reported in 58% of the patients 
receiving A+AVD and in 45% of the patients receiving ABVD, and febrile neutropenia was 
reported in 19% and 8%, respectively. In both groups, the incidence of febrile neutropenia 
was higher among patients 60 years of age or older than among those younger than 60 years 
of age (37% vs. 17% in the A+AVD group and 17% vs. 6% in the ABVD group). The 
incidence of febrile neutropenia was also higher in earlier rather than later cycles of therapy 
in both groups (9% in cycle 1 vs. 1 to 6% in cycles 2 through 6 in the A+AVD group and 4% 
in cycle 1 vs. ≤1% in cycles 2 through 6 in the ABVD group). The incidence of 
discontinuation of any trial drug due to neutropenia or febrile neutropenia was 1% or less in 
both groups.
The rate of infections (determined in accordance with the MedDRA primary system organ-
class term of “infections and infestations”) in the A+AVD group was 55% (361 of 662 
patients) and the rate in the ABVD group was 50% (331 of 659 patients); rates of infection 
of grade 3 or higher were 18% (116 of 662 patients) and 10% (66 of 659 patients), 
respectively. Discussion with the independent data and safety monitoring committee (after 
76% of enrollment was complete) led to the recommendation of primary prophylaxis with 
granulocyte colony-stimulating factor (G-CSF) for patients who were yet to be enrolled and 
who would receive the A+AVD regimen, owing to the higher incidence of febrile 
neutropenia in that group. In the A+AVD group, the incidence of febrile neutropenia was 
lower among the 83 patients who received primary prophylaxis with G-CSF (defined as use 
of G-CSF by day 5 of treatment) than among those who did not (11% [9 of 83] vs. 21% [119 
of 579]) (Table 5). The occurrence of infections and infestations of grade 3 or higher was 
also lower among the patients who received G-CSF than among those who did not (11% [9 
of 83 patients] vs. 18% [107 of 579 patients]).
Peripheral neuropathy (determined on the basis of a standardized MedDRA query; see Table 
S8 in the Supplementary Appendix) occurred in 67% of the patients (442 of 662) receiving 
A+AVD and 43% of the patients (286 of 659) receiving ABVD. Grade 2 peripheral 
neuropathy occurred in 20% of the patients (130 of 662) in the A+AVD group versus 9% of 
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the patients (57 of 659) in the ABVD group, and peripheral neuropathy of grade 3 or higher 
occurred in 11% of the patients (70 of 662) in the former group (with grade 4 occurring in 1 
patient) versus 2% of the patients (11 of 659) in the latter. Among patients with peripheral 
neuropathy, a trial drug was discontinued in 10% in the A+AVD group (44 of 442) versus 
4% in the ABVD group (11 of 286). Two thirds of the patients in the A+AVD group (295 of 
442) who had peripheral neuropathy had resolution (43%, 191 of 442) or improvement by at 
least one grade (24%, 104 of 442) in terms of events related to peripheral neuropathy at the 
time of the last follow-up visit; at that time, 92% of ongoing events related to peripheral 
neuropathy were grade 1 (64%) or grade 2 (29%) in the A+AVD group. Pulmonary toxicity, 
defined as events related to interstitial lung disease (in accordance with a standardized 
MedDRA query), was reported in 2% of the patients (12 of 662) in the A+AVD group versus 
7% (44 of 659) in the ABVD group; events of grade 3 or higher were reported in less than 
1% of the patients (5 of 662) in the former group and 3% of the patients (21 of 659) in the 
latter.
During treatment, there were 9 deaths in the A+AVD group and 13 deaths in the ABVD 
group. In the A+AVD group, 7 deaths were associated with neutropenia (all occurred in 
patients who had not received primary prophylaxis with G-CSF before the onset of 
neutropenia, with the exception of 1 patient who entered the trial with preexisting 
neutropenia) and 2 deaths were due to myocardial infarction. In the ABVD group, 11 deaths 
were due to or associated with pulmonary-related toxicity and 1 death was due to 
cardiopulmonary failure. The cause of 1 death was unknown. Among the patients enrolled in 
the trial, 37% (242 of 662) in the A+AVD group and 28% (186 of 659) in the ABVD group 
were hospitalized during the trial.
Fertility was not formally assessed; however, similar numbers of pregnancies were reported 
in each treatment group, which suggests that there was no significant difference in the effect 
on fertility. At the time of this analysis, a total of 78 pregnancies were reported among trial 
participants and their partners (42 in the A+AVD group and 36 in the ABVD group).
DISCUSSION
This large, international, randomized phase 3 trial involving patients who had received a 
recent diagnosis of stage III or IV classic Hodgkin’s lymphoma showed that treatment with 
brentuximab vedotin plus AVD, as compared with standard treatment with ABVD, resulted 
in a statistically significant and clinically meaningful improvement in the rate of modified 
progression-free survival, with a difference at 2 years of 4.9 percentage points as assessed by 
an independent committee, whose members were unaware of group assignments and 6.6 
percentage points as assessed by the trial investigators. These outcomes were associated with 
reductions in the overall risk of failure of the primary chemotherapy treatment of 23% as 
assessed by an independent review committee and 27% as assessed by the trial investigators.
The goal of frontline chemotherapy for Hodgkin’s lymphoma is to cure patients without the 
need for additional therapy. Because metabolically detectable residual disease is a reliable 
predictor of imminent progression, it is accepted practice to initiate subsequent 
chemotherapy or radiotherapy on the basis of a positive PET scan at the end of frontline 
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treatment.21–23 In this context, the conventional end point of progression-free survival does 
not accurately assess the curative intent of frontline chemotherapy. Thus, in the 
ECHELON-1 trial, the primary end point was “modified” progression-free survival, which, 
in addition to disease progression or death, included modified progression, defined as 
evidence of non-complete response after the completion of front-line chemotherapy (based 
on independently assessed PET results) followed by subsequent anticancer therapy, as an 
event, thus accurately assessing the curative potential of the frontline chemotherapy.
The results of the interim overall survival analysis and all other secondary efficacy end 
points favored A+AVD, further supporting the conclusion that A+AVD is a more effective 
front-line treatment for advanced Hodgkin’s lymphoma than ABVD. Furthermore, the 
benefit of A+AVD was observed consistently in the majority of prespecified subgroups, 
including patients in whom there was involvement of more than one extranodal site, patients 
with an IPS indicating high risk for treatment failure (4 to 7), and patients with stage IV 
disease. The rate of positivity at PET2 was low, and a higher proportion of the patients 
treated with A+AVD than those treated with ABVD had negative results at PET2 (89% vs. 
86%).
This trial shows that the addition of brentuximab vedotin and the elimination of bleomycin 
from frontline therapy in the A+AVD regimen lowers the incidence of pulmonary toxicity 
while improving efficacy as compared with the ABVD regimen. No new types of risk to 
patient safety were identified, although the incidence of febrile neutropenia was higher than 
expected and an increased incidence of infections was noted in the A+AVD group. The 
majority of the deaths during treatment in the A+AVD group were associated with febrile 
neutropenia; however, primary prophylaxis with G-CSF appeared to mitigate the increased 
risk of febrile neutropenia and its sequelae in the subgroup of 83 patients who received 
primary prophylaxis, resulting in reduced rates of neutropenia, febrile neutropenia, and 
serious infection. Peripheral neuropathy occurred more frequently in patients in the A+AVD 
group. The incidence of peripheral neuropathy of grade 3 or higher was increased by 9 
percentage points in this group as compared with the ABVD group, and peripheral 
neuropathy was largely reversible, either resolving or abating in 67% of the patients in 
whom the condition had developed. Both the percentage of patients who received 
subsequent salvage chemotherapy and the percentage of patients who received high-dose 
chemotherapy followed by transplantation were approximately 33% lower among patients 
treated with A+AVD than among patients treated with ABVD; those treated with A+AVD 
were therefore less likely to be subject to the toxicities associated with aggressive salvage 
therapies.
The results of the ECHELON-1 trial are particularly important considering the opportunity 
A+AVD provides to administer a treatment to older patients that is at least equivalent in its 
effectiveness to ABVD, and to do so safely. Older patients with advanced Hodgkin’s 
lymphoma represent a special group, considering their incidence of disease (approximately 
20% of all cases), lower rates of treatment efficacy, and typically higher rates of severe 
toxicity, particularly the pulmonary toxicity that is associated with bleomycin.6,24,25 When 
choosing frontline treatment, it is important to consider the lifetime burden of late and long-
term adverse effects from salvage chemotherapy, radiotherapy, and transplantation 
Connors et al. Page 9
N Engl J Med. Author manuscript; available in PMC 2018 February 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
(including infertility, pulmonary and cardiac toxicities, and secondary cancers).26,27 The A
+AVD regimen is associated with more myelotoxicity (which can be ameliorated with 
prophylactic G-CSF) and neurotoxicity (which is largely reversible) than ABVD but 
substantially less pulmonary toxicity and appears to be more effective for the frontline 
treatment of advanced-stage classic Hodgkin’s lymphoma.
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Figure 1. Modified Progression-free Survival in the Intention-to-Treat Population
Panel A shows Kaplan–Meier estimates of modified progression-free survival, by treatment 
group, according to the independent review committee. The hazard ratio for treatment with 
A+AVD versus ABVD and the 95% confidence intervals (CIs) were based on a stratified 
Cox proportional-hazards regression model, with treatment as the explanatory variable. 
Stratification factors included region and International Prognostic Score risk group at 
baseline. Panel B shows Kaplan–Meier estimates of modified progression-free survival, by 
treatment group, according to investigators. In Panels A and B, circles indicate censored 
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data. A+AVD denotes brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine, 
and ABVD doxorubicin, bleomycin, vinblastine, and dacarbazine.
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Figure 2. Forest-Plot Analysis of Modified Progression-free Survival
This forest plot shows modified progression-free survival according to the independent 
review committee in key prespecified subgroups. The hazard ratio for treatment with A
+AVD versus ABVD and the 95% confidence intervals (CIs) were based on an unstratified 
Cox proportional-hazards regression model, with treatment as the explanatory variable. The 
intention-to-treat population included all the patients who underwent randomization. The 
International Prognostic Score (IPS) ranges from 0 to 7, with higher scores indicating 
increased risk of treatment failure: low risk, 0 or 1; intermediate risk, 2 or 3; and high risk, 4 
to 7. The Ann Arbor staging system ranges from I to IV, with higher stages indicating more 
widespread disease. B symptoms consist of night sweats, unexplained fever (temperature 
>38°C), or loss of more than 10% of body weight. Values for the Eastern Cooperative 
Oncology Group (ECOG) performance status range from 0 to 5, with higher scores 
indicating greater disability.
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Table 1
Patient Demographic and Clinical Characteristics at Baseline (Intention-to-Treat Population).*
Characteristic
A+AVD
(N = 664)
ABVD
(N = 670)
Total
(N = 1334)
Male sex — no. (%) 378 (57) 398 (59) 776 (58)
Age — yr
 Median 35 37 36
 Range 18–82 18–83 18–83
Age categories — no. (%)
 <45 yr 451 (68) 423 (63) 874 (66)
 45–59 yr 129 (19) 145 (22) 274 (21)
 60–64 yr 24 (4) 40 (6) 64 (5)
 ≥65 yr 60 (9) 62 (9) 122 (9)  
Regions — no. (%)
 Americas 261 (39) 262 (39) 523 (39)
 Europe 333 (50) 336 (50) 669 (50)
 Asia   70 (11)   72 (11) 142 (11)
Ann Arbor stage at initial diagnosis — no. (%)†
 Stage II‡     1 (<1) 0     1 (<1)
 Stage III 237 (36) 246 (37) 483 (36)
 Stage IV 425 (64) 421 (63) 846 (64)
 Not applicable, unknown, or missing     1 (<1)     3 (<1)     4 (<1)
International Prognostic Score — no. (%)§
 0 or 1 141 (21) 141 (21) 282 (21)
 2 or 3 354 (53) 351 (52) 705 (53)
 4 to 7 169 (25) 178 (27) 347 (26)
ECOG performance status — no. (%)¶
 0 376 (57) 378 (57) 754 (57)
 1 259 (39) 262 (39) 521 (39)
 2 28 (4) 26 (4) 54 (4)
 Not obtained or missing     1 (<1)     4 (<1)     5 (<1)
Extranodal involvement at diagnosis — no. (%)
 Yes 411 (62) 416 (62) 827 (62)
  1 extranodal site 217 (33) 223 (33) 440 (33)
  >1 extranodal sites 194 (29) 193 (29) 387 (29)
 No 217 (33) 228 (34) 445 (33)
 Unknown or missing 36 (5) 26 (4) 62 (5)
Patients with any B symptom — no. (%)‖ 399 (60) 381 (57) 780 (58)
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*A full description of patient demographics and clinical characteristics at baseline can be found in Table S3 in the Supplementary Appendix. 
Percentages may not total 100 because of rounding. A+AVD denotes brentuximab vedotin plus doxorubicin, vinblastine, dacarbazine, and ABVD 
doxorubicin, bleomycin, vinblastine, and dacarbazine.
†
The Ann Arbor staging system ranges from I to IV, with higher stages indicating more widespread disease.
‡
Patients in this category had a major protocol violation.
§
The International Prognostic Score ranges from 0 to 7, with higher scores indicating increased risk of treatment failure. Scores of 0 to 1 denote 
low risk, scores of 2 to 3 intermediate risk, and scores of 4 to 7 high risk.
¶Values for Eastern Cooperative Oncology Group (ECOG) performance status range from 0 to 5, with higher scores indicating greater disability.
‖
B symptoms consist of night sweats, unexplained fever (temperature >38°C), or loss of more than 10% of body weight.
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Table 2
Summary of Modified Progression-free Survival According to the Independent Review Committee and 
Concordance with Events Noted by Trial Investigators (Intention-to-Treat Population).
Events
A+AVD
(N = 664)
ABVD
(N = 670)
Total
(N = 1334)
Patients with events per independent review committee — no. 117 146 263
Progression — no./total no. (%) 90/117 (77) 102/146 (70) 192/263 (73)
Death — no./total no. (%) 18/117 (15) 22/146 (15) 40/263 (15)
Positive PET scan and subsequent treatment — no./total no. (%)* 9/117 (8) 22/146 (15) 31/263 (12)
Patients with positive PET scan and subsequent treatment — no. 9 22 31
Salvage chemotherapy — no./total no. (%)† 7/9 (78) 15/22 (68) 22/31 (71)
 Met criteria for PFS event
  PFS event or modified event reported by investigator — no. 7 15 22
 PFS event reported by investigator — no./total no. (%) 7/7 (100) 13/15 (87) 20/22 (91)
  PFS event reported by independent review committee — no./total no. (%) 2/7 (29) 3/15 (20) 5/22 (23)
 Deauville score at end of treatment — no./total no. (%)‡
  1 0 0 0
  2 0 0 0
  3 0 2/15 (13) 2/22 (9)
  4 3/7 (43) 4/15 (27) 7/22 (32)
  5 4/7 (57) 9/15 (60) 13/22 (59)
Radiation — no./total no. (%) 2/9 (22) 7/22 (32) 9/31 (29)
 Met criteria for PFS event
  PFS event or modified event reported by investigator — no. 2 7 9
  PFS event reported by investigator — no./total no. (%) 0 1/7 (14) 1/9 (11)
  PFS event reported by independent review committee — no./total no. (%) 0 1/7 (14) 1/9 (11)
 Deauville score at end of treatment — no./total no. (%)‡
  1 0 0 0
  2 0 0 0
  3 2/2 (100) 3/7 (43) 5/9 (56)
  4 0 3/7 (43) 3/9 (33)
  5 0 1/7 (14) 1/9 (11)
*
There were 58 patients at risk for a modified progression event (end-of-treatment Deauville score ≥3 and no progressive disease at the end of 
treatment): 19 in the group receiving A+AVD versus 39 in the group receiving ABVD. However, only 9 patients in the A+AVD group and 22 
patients in the ABVD group actually had a modified progression event because they received subsequent treatment. PET denotes positron-emission 
tomography, and PFS progression-free survival.
†Salvage chemotherapy included the terms chemotherapy, high-dose chemotherapy plus transplantation, and immunotherapy according to medical 
review.
‡
The Deauville score is a 5-point scale on which higher scores indicate greater uptake of 18F-fluorodeoxyglucose at involved sites on PET. A score 
of 1 indicates no uptake, a score of 2 uptake at an initial site that is less than or equal to the uptake at the mediastinum, a score of 3 uptake at an 
initial site that is greater than uptake at the mediastinum but less than or equal to uptake at the liver, a score of 4 uptake at an initial site that is 
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moderately increased as compared with uptake at the liver, and a score of 5 markedly increased uptake at any site or uptake at a new site of disease. 
The absence of complete response at the end of primary chemotherapy was defined as a Deauville score of 3, 4, or 5.
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Table 3
Summary of Responses in the Intention-to-Treat Population.
Measure
A+AVD
(N = 664)
ABVD
(N = 670)
Difference
(95% CI)*
no. (%) %
Complete response at end of randomized regimen† 488 (73) 472 (70) 3.0 (−2.3 to 8.4)
Overall response at end of randomized regimen‡ 569 (86) 553 (83) 3.2 (−2.2 to 8.6)
Complete response at end of frontline therapy§ 488 (73) 474 (71) 2.7 (−2.6 to 8.1)
Deauville score¶
≤3 After completion of frontline therapy) 570 (86) 551 (82) 3.6 (−1.8 to 9.0)
≤2 After completion of frontline therapy 563 (85) 537 (80) 4.6 (−0.8 to 10.0)
Summary at cycle 2
 1 435 (66) 414 (62)
 2 131 (20) 133 (20)
 3 22 (3) 30 (4)
 4 26 (4) 28 (4)
 5 21 (3) 30 (4)
 Unavailable 29 (4) 35 (5)
Summary after completion of primary chemotherapy
 1 444 (67) 425 (63)
 2 119 (18) 112 (17)
 3   7 (1) 14 (2)
 4 12 (2) 20 (3)
 5 46 (7) 45 (7)
 Unavailable 36 (5) 54 (8)
*Confidence intervals (CIs) were calculated from the exact confidence interval, have not been adjusted for the multiple comparisons, and should 
not be used for definitive comparisons.
†Complete response at the end of the randomized regimen is defined as the proportion of patients who had complete response20 at the end of 
treatment with either regimen (A+AVD or ABVD).
‡Overall response at the end of the randomized regimen is defined as the proportion of patients who had complete or partial response20 at the end 
of treatment with either regimen (A+AVD or ABVD).
§Complete response at the end of frontline therapy is defined as the proportion of patients who had complete response after the completion of either 
the randomized regimen (A+AVD or ABVD) or alternate frontline therapy.
¶
The Deauville score is a 5-point scale on which higher scores indicate greater uptake of 18F-fluorodeoxyglucose at involved sites on PET. A score 
of 1 indicates no uptake, a score of 2 uptake at an initial site that is less than or equal to the uptake at the mediastinum, a score of 3 uptake at an 
initial site that is greater than uptake at the mediastinum but less than or equal to uptake at the liver, a score of 4 uptake at an initial site that is 
moderately increased as compared with uptake at the liver, and a score of 5 markedly increased uptake at any site or uptake at a new site of disease. 
The absence of complete response at the end of primary chemotherapy was defined as a Deauville score of 3, 4, or 5.
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Table 4
Summary of Adverse Events in the Safety Population.*
Events
A+AVD
(N = 662)
ABVD
(N = 659)
no. (%)
Adverse events
Any adverse event 653 (99) 646 (98)
Grade ≥3 adverse event 549 (83) 434 (66)
Serious adverse event 284 (43) 178 (27)
Adverse event resulting in drug discontinuation   88 (13) 105 (16)
Death during treatment†   9 (1) 13 (2)
Death due to drug-related adverse events   8 (1)   7 (1)
Hospitalizations 242 (37) 186 (28)
Common adverse events‡
Neutropenia
 Any grade 382 (58) 295 (45)
 Grade ≥3 357 (54) 260 (39)
Constipation
 Any grade 279 (42) 241 (37)
 Grade ≥3 11 (2)     4 (<1)
Vomiting
 Any grade 216 (33) 183 (28)
 Grade ≥3 23 (3)   9 (1)
Fatigue
 Any grade 211 (32) 211 (32)
 Grade ≥3 19 (3)   7 (1)
Peripheral sensory neuropathy
 Any grade 189 (29) 111 (17)
 Grade ≥3 31 (5)     3 (<1)
Diarrhea
 Any grade 181 (27) 121 (18)
 Grade ≥3 19 (3)     5 (<1)
Pyrexia
 Any grade 179 (27) 147 (22)
 Grade ≥3 19 (3) 13 (2)
Peripheral neuropathy
 Any grade 174 (26)   85 (13)
 Grade ≥3 27 (4)     6 (<1)
Abdominal pain
 Any grade 142 (21)   65 (10)
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Events
A+AVD
(N = 662)
ABVD
(N = 659)
no. (%)
 Grade ≥3 21 (3)     4 (<1)
Stomatitis
 Any grade 138 (21) 104 (16)
 Grade ≥3 10 (2)     3 (<1)
*
For a full summary of adverse events, including rates of drug-related adverse events and deaths, see Table S7 in the Supplementary Appendix.
†
Death during treatment is a death that occurred within 30 days after the last dose of frontline therapy.
‡
The events listed include the most clinically important common adverse events. Adverse events (those of any grade that occurred in at least 20% 
of the patients in either group) excluded from the table are nausea, alopecia, weight loss, and anemia.
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Table 5
Summary of Adverse Events in Patients Who Did and Those Who Did Not Receive Primary Prophylaxis with 
Granulocyte Colony-Stimulating Factor.
Events
A+AVD
(N = 662)
ABVD
(N = 659)
No
(N = 579)
Yes
(N = 83)
No
(N = 616)
Yes
(N = 43)
number (percent)
Febrile neutropenia during treatment 119 (21) 9 (11) 49 (8) 3 (7)
Any neutropenia* 425 (73) 29 (35) 352 (57) 9 (21)
Neutropenia grade ≥3* 406 (70) 24 (29) 309 (50) 8 (19)
Grade ≥3 adverse event 502 (87) 47 (57) 414 (67) 20 (47)
Infections and infestations (SOC) 322 (56) 39 (47) 312 (51) 19 (44)
Grade ≥3 infections and infestations (SOC) 107 (18) 9 (11) 63 (10) 3 (7)
Serious adverse event 257 (44) 27 (33) 171 (28) 7 (16)
Serious adverse events of febrile neutropenia, neutropenia, sepsis, neutropenic sepsis, 
pyrexia, or infections and infestations (SOC)
190 (33) 20 (24) 107 (17) 4 (9)
Deaths during treatment† 8 (1) 1 (1)‡ 12 (2) 1 (2)
*Neutropenia and neutropenia grade 3 or higher (neutrophil count <1000 per cubic millimeter) include the preferred terms of “neutropenia” and 
“neutrophil count decreased.” SOC denotes system organ class for the noted event.
†
Death during treatment is a death that occurred within 30 days after the last dose of frontline therapy.
‡
The patient in the A+AVD group who had G-CSF primary prophylaxis received G-CSF for treatment of neutropenia, which occurred before day 5.
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